Sponsors

Lead Sponsor

Eastern Cooperative Oncology Group

Collaborators

National Cancer Institute (NCI)

OBJECTIVES: * To test the influence of killer immunoglobulin-like receptor (KIR) and human lymphocyte antigen (HLA) genotype on response to anti-CD20 antibody lymphoma immunotherapy. OUTLINE: DNA samples are analyzed for killer immunoglobulin-like receptor (KIR) and human lymphocyte antigen (HLA) genotyping with sequence-specific primers (SSP) by real-time PCR. KIR and HLA typing are analyzed according to KIR-HLA matched vs mismatched, KIR B haplotype content, and the number of inhibitory KIR-HLA pairs. Results are then correlated to each patient's overall response and duration of response to rituximab.

Related studies

RECRUITING

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

NCT05237986 · Lymphoma, Leukemia

RECRUITING

Tissue Collection for Studies of Lymph Cancer

NCT01676805 · Hodgkin Disease, Lymphoma, Non-Hodgkin, and more

View all related studies →

DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

Tissue Collection for Studies of Lymph Cancer

Trial snapshot

Condition

For caregivers